JAMA Psychiatry | Original Investigation

Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations

Yuri Milaneschi, PhD; Femke Lamers, PhD; Wouter J. Peyrot, MD, PhD;
Bernhard T. Baune, MD, PhD, MPH, FRANZCP; Gerome Breen, PhD; Abbas Dehghan, MD, PhD;
Andreas J. Forstner, MD; Hans J. Grabe, MD; Georg Homuth, PhD; Carol Kan, MA, MBBS, MRCPsych;
Cathryn Lewis, PhD; Niamh Mullins, PhD; Matthias Nauck, MD; Giorgio Pistis, PhD; Martin Preisig, MD, MPH;
Margarita Rivera, PhD; Marcella Rietschel, MD; Fabian Streit, MD; Jana Strohmaier, PhD; Alexander Teumer, PhD;
Sandra Van der Auwera, PhD; Naomi R. Wray, PhD; Dorret I. Boomsma, PhD; Brenda W. J. H. Penninx, PhD;
for the CHARGE Inflammation Working Group and the Major Depressive Disorder Working Group
of the Psychiatric Genomics Consortium

IMPORTANCE The association between major depressive disorder (MDD) and obesity may stem from shared immunometabolic mechanisms particularly evident in MDD with atypical features, characterized by increased appetite and/or weight (A/W) during an active episode.

OBJECTIVE To determine whether subgroups of patients with MDD stratified according to the A/W criterion had a different degree of genetic overlap with obesity-related traits (body mass index [BMI] and levels of C-reactive protein [CRP] and leptin).

DESIGN, SETTING, AND PATIENTS This multicenter study assembled genome-wide genotypic and phenotypic measures from 14 data sets of the Psychiatric Genomics Consortium. Data sets were drawn from case-control, cohort, and population-based studies, including 26 628 participants with established psychiatric diagnoses and genome-wide genotype data. Data on BMI were available for 15 237 participants. Data were retrieved and analyzed from September 28, 2015, through May 20, 2017.

MAIN OUTCOMES AND MEASURES Lifetime *DSM-IV* MDD was diagnosed using structured diagnostic instruments. Patients with MDD were stratified into subgroups according to change in the *DSM-IV* A/W symptoms as decreased or increased.

RESULTS Data included 11 837 participants with MDD and 14 791 control individuals, for a total of 26 628 participants (59.1% female and 40.9% male). Among participants with MDD, 5347 (45.2%) were classified in the decreased A/W and 1871 (15.8%) in the increased A/W subgroups. Common genetic variants explained approximately 10% of the heritability in the 2 subgroups. The increased A/W subgroup showed a strong and positive genetic correlation (SE) with BMI (0.53 [0.15]; $P = 6.3 \times 10^{-4}$), whereas the decreased A/W subgroup showed an inverse correlation (-0.28 [0.14]; $P = .06$). Furthermore, the decreased A/W subgroup had a higher polygenic risk for increased BMI (odds ratio [OR], 1.18; 95% CI, 1.12-1.25; $P = 1.6 \times 10^{-10}$) and levels of CRP (OR, 1.08; 95% CI, 1.02-1.13; $P = 7.3 \times 10^{-3}$) and leptin (OR, 1.09; 95% CI, 1.06-1.12; $P = 1.7 \times 10^{-3}$).

CONCLUSIONS AND RELEVANCE The phenotypic associations between atypical depressive symptoms and obesity-related traits may arise from shared pathophysiologic mechanisms in patients with MDD. Development of treatments effectively targeting immunometabolic dysregulations may benefit patients with depression and obesity, both syndromes with important disability.

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: Members of the CHARGE Inflammation Working Group and the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium are listed at the end of the article.

Corresponding Author: Yuri Milaneschi, PhD, Department of Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience, Vrije Universiteit Medical Center and GGZ inGeest, AJ Ernststraat 1187, 1081 HL Amsterdam, the Netherlands (y.milaneschi@ggzingeest.nl).

Epidemiologic evidence has identified robust associations between depression and obesity.[1,2] This link may be attributable to shared pathophysiologic mechanisms, such as immunometabolic pathways characterized by increased proinflammatory response and dysregulation of homeostatic hormones responsible for energy metabolism.[3] Obesity is characterized by low-grade proinflammatory activation.[4] Peripheral immune activation could trigger brain inflammatory responses participating in depressive neurochemical and/or endocrine processes (ie, depletion and degradation of tryptophan toward neurotoxic end products[5] or hyperactivation of the hypothalamic-pituitary-adrenal axis[6]). Disrupted central signaling of the adipocyte-derived hormone leptin (suppressing food intake and promoting energy expenditure[7]) may influence mood. Development of central functional resistance blunts leptin anorexigenic (disinhibiting feeding[7]), procognitive, and antidepressant effects.[8-10] Leptin mood regulation may be exerted directly via receptors expressed in the hippocampus and amygdala by influencing neurogenesis and neuroplasticity in the hippocampus and cortex or by modulating the hypothalamic-pituitary-adrenal axis.[11-13]

Establishing the role in depression of such mechanisms has been difficult. Although meta-analytic evidence provides mean effect sizes, strength and direction of the associations of depression with obesity-related indexes and biomarkers may vary considerably across different subgroups of patients owing to clinical heterogeneity. In the past decade, evidence has emerged suggesting that the link between depression and immunometabolic dysregulations is stronger, or specific, for MDD with atypical features, such as increased appetite and/or weight (A/W) and hypersomnia.[14-23] Other clinical characteristics linked to atypical depression are preponderance of female sex, earlier age at onset, and higher severity.[24,25] Specific atypical symptoms may constitute major axes of variation for the associations of MDD with obesity-related features. Recently, the Netherlands Study of Depression and Anxiety (NESDA) showed that increased appetite during an active depressive episode was more strongly associated with body mass index (BMI) and levels of C-reactive protein (CRP)[26] and leptin.[27] Other atypical symptoms that commonly cluster with increased appetite showed a weaker association (increased weight)[27] or no association (hypersomnia)[26,27] with these markers. Whether this covariance between depressive symptoms and obesity-related traits reflects shared genetic liabilities needs to be established. In prior work[28,29] including approximately 3000 Dutch individuals, the contribution of BMI risk variants could be specifically detected only in patients with MDD who endorsed increased A/W symptoms.

In the present study, we scaled up genetic analyses to more than 25 000 samples from different countries from the Psychiatric Genomics Consortium (PGC) with established psychiatric diagnoses and genome-wide association study (GWAS) data. Compared with the latest study,[29] we were able to estimate the genetic correlations between BMI and MDD subgroups. Furthermore, we derived polygenic risk scores with enhanced predictive accuracy owing to larger discovery samples and newly developed methods. Finally, we included leptin polygenic risk scores previously not investigated. First, after strati-

Key Points

Question Is the genetic overlap with obesity-related traits (body mass index and levels of C-reactive protein and leptin) stronger in patients with major depression and the atypical symptoms of increased appetite and/or weight during an active episode?

Findings Data from a large international consortium showed that patients with depression and increased appetite and/or weight (approximately 15% of cases) carried a higher number of genetic risk variants for body mass index and levels of C-reactive protein and leptin.

Meaning The established phenotypic associations between atypical depressive symptoms and obesity-related traits may arise from shared pathophysiologic mechanisms, and development of treatments effectively targeting immunometabolic dysregulations may benefit this subgroup of patients.

fying patients according to A/W symptoms during the MDD index episodes, we validated the resulting subgroups against established clinical characteristics. Next, we estimated the contribution of common genetic variants to the underlying liabilities of the subgroups and their reciprocal correlations. Finally, we tested whether the subgroups had a differential genetic overlap with BMI and levels of CRP and leptin. Based on previous findings,[28,29] we hypothesized a specific underlying connection between immunometabolic traits and patients with MDD endorsing the *DSM-IV* increased A/W symptoms.

Methods

Study Sample

Data were derived from the PGC MDD Working Group (PGC-MDD2) (http://www.biorxiv.org/content/early/2017/07/24/167577), which assembled genome-wide genotypic and phenotypic measures from 29 data sets (24 contributing cohorts), including 42 455 samples of European ancestry. Eleven data sets did not provide *DSM* items coding for A/W; in addition, 4 data sets were excluded owing to very low endorsement (<14 samples) of A/W symptoms. Thus, the main analytic sample (**Table 1**) was based on the remaining 14 data sets totaling 26 628 participants, of whom 11 837 had MDD (cases diagnosed according to *DSM-IV* lifetime MDD using structured diagnostic instruments, clinician-administered *DSM-IV* checklists, or medical record) and 14 791 were control individuals (screened in 11 of 14 data sets). Data collection was approved by each center's local institutional review board or medical ethics committee (all participating centers are listed at the end of the article), which waived the need for informed consent for use of the deidentified data sets.

Stratification of MDD Cases

Data were retrieved and analyzed from September 28, 2015, through May 20, 2017. The selected data sets included information on *DSM-IV* MDD symptoms endorsed during the index depressive episode. Items on neurovegetative symptoms were disaggregated to code separately for increase and decrease. As in previous work,[29] stratification of MDD cases in

Table 1. Characteristics of the PGC Data Sets Selected

Data Set	Country	Sample, No.	Female, No. (%)	No. of Control Individuals	MDD Status[a]			
					No. of Patients	A/W Subtype, No. (%)		
						Decreased	No Change	Increased
BOMA	Germany	1648	895 (54.3)	1062	586	355 (60.6)	146 (24.9)	55 (9.4)
PsyCoLaus	Switzerland	1952	976 (50.0)	1445	507	246 (48.5)	205 (40.4)	56 (11.0)
GenRED1	United States	2363	1283 (54.3)	1344	1019	499 (49.0)	210 (20.6)	253 (24.8)
GenRED2	United States	1304	919 (70.5)	474	830	404 (48.7)	170 (20.5)	190 (22.9)
GSK/MPIP	Germany	1741	1171 (67.3)	861	880	552 (62.7)	229 (26.0)	67 (7.6)
NESDA/NTR	Netherlands	3096	1996 (64.4)	1602	1494	548 (36.7)	415 (27.8)	349 (23.4)
QIMR substudy qi3c	Australia	1443	870 (60.3)	579	864	369 (42.7)	307 (35.5)	129 (14.9)
QIMR substudy qi6c	Australia	1089	713 (65.5)	590	499	153 (30.7)	189 (37.9)	50 (10.0)
QIMR substudy qio2	Australia	1091	708 (64.8)	526	565	203 (35.9)	222 (39.3)	73 (12.9)
RADIANT-United Kingdom	United Kingdom	3269	2158 (66.0)	1397	1872	948 (50.6)	395 (21.1)	279 (14.9)
RADIANT-Germany	Germany	549	330 (60.1)	227	322	174 (54.0)	89 (27.6)	44 (13.7)
SHIP0	Germany	1453	726 (50.0)	1087	366	205 (56.0)	109 (29.8)	34 (9.3)
STAR*D	United States	1870	986 (52.7)	934	936	291 (31.1)	290 (31.0)	197 (21.0)
TwinGene	Sweden	3760	1978 (51.9)	2663	1097	400 (36.5)	445 (40.6)	95 (8.7)

Abbreviations: A/W, appetite and/or weight symptoms; BOMA, Bonn/Mannheim Study; GenRED, Genetics of Recurrent Early-Onset Depression; GSK/MPIP, GlaxoSmithKline/Max Planck Institute of Psychiatry; MDD, major depressive disorder; NESD/NTR, Netherlands Study of Depression and Anxiety/Netherlands Twin Registry; PGC, Psychiatric Genomics Consortium; PsyCoLaus, psychiatric arm of Cohorte Lausannoise; QIMR, Queensland Institute of Medical Research; SHIP0, Study of Health in Pomerania; STAR*D, Sequenced Treatment Alternatives to Relieve Depression study.

[a] A small proportion of cases, set as missing, could not be classified owing to reporting simultaneously reported increase and decrease in the 2 items (5.9%) or owing to missing both items (4.2%).

all data sets was based on 2 items coding separately for decrease in A/W and increase in A/W. Among the patients with MDD, the following 3 subgroups were identified (Table 1 and eMethods 1 in the Supplement): decreased A/W (5347 [45.2%]), no change (3421 [28.9%]), and increased A/W (1871 [15.8%]).

Additional Phenotypes

Information on age at onset was available for 10 452 patients with MDD (eTable 1 in the Supplement). The number of endorsed symptoms calculated as the sum of *DSM-IV*–positive criteria (range, 5-12; 3 symptoms disaggregated in 6 items coding separately for increase or decrease) to index overall severity was available in 10 991 cases. Analyses using BMI were based on 2 panels of data sets, including 9 data sets providing BMI for 15 237 samples (42%-100% of the samples across data sets; the GlaxoSmithKline/Max Planck Institute of Psychiatry and Sequenced Treatment Alternatives to Relieve Depression studies were excluded owing to lack of BMI data; the Bonn/Mannheim Study, RADIANT–United Kingdom, and RADIANT–Germany were excluded owing to availability of BMI in <18% of samples) and 7 data sets providing BMI for 13 448 samples (83%-100% of the samples across data sets; additional removal of Genetics of Recurrent Early-Onset Depression studies 1 and 2 providing BMI only in cases).

Genotype Data Selection

Genotype data underwent centralized quality control and imputation as extensively described in the PGC-MDD2 GWAS (http://www.biorxiv.org/content/early/2017/07/24/167577). Two panels of single-nucleotide polymorphisms (SNPs) were selected for the present analyses (eMethods 1 in the Supplement). The first panel of 1 169 543 SNPs passing postimputation quality

control in at least 2 of 14 data sets and present in the HapMap3 reference was selected to build a genomic relationship matrix (eTable 2 in the Supplement). The second panel of 2 548 638 SNPs passing quality control in all 14 data sets constituted the base to build genomic profile risk scores (GPRSs).

Genomic Profile Risk Scores

We used GWAS meta-analyses from large international consortia to generate the following obesity-related trait GPRSs (eMethods 1 in the Supplement): BMI (approximately 160 000 samples)[30] and circulating blood concentrations of CRP (approximately 70 000 samples),[31] leptin, and BMI-adjusted leptin (approximately 32 000 samples).[32] Psychiatric trait GPRSs were also built, including schizophrenia (approximately 36 000 patients and 113 000 controls)[33] and MDD (approximately 50 000 patients and 110 000 controls) (http://www.biorxiv.org/content/early/2017/07/24/167577). Overlapping SNPs (approximately 400 000 to 700 000) between the approximately 2.5 million selected and those filtered from the discovery GWAS were used to build GPRSs with linkage disequilibrium (LD) according to the LDpred method,[34] which has shown an improved predictive performance compared with other methods by modeling a prior on effect sizes and LD information. The fraction of causal SNPs was set at 5%, consistent with the estimate for schizophrenia.[35]

Statistical Analysis

Analyses are extensively described in eMethods 1 and URLs of the software used in the analyses are given in eMethods 2 in the Supplement. In brief, differences in sex, age at onset, number of *DSM-IV* symptoms, and sex-adjusted BMI across the subgroups of patients were examined. Data were pooled using a multilevel analysis approach with (generalized) linear mixed

Figure 1. Phenotype Validation Against Established Clinical Characteristics

Differences in sex, age at onset, number of *DSM-IV* symptoms, and sex-adjusted body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) are shown across subgroups of patients with major depressive disorder (MDD). The patients were compared by subgroups with increased appetite and/or weight symptoms (A/W), decreased A/W, or no change using generalized linear mixed models. A, Raw data for female patients include 3758 (70.3%) for the decreased A/W subgroup, 2141 (62.6%) for the no-change subgroup, and 1430 (76.4%) for the increased A/W subgroup. B, Estimated mean (SE) age at onset was 30.1 (2.3) years in the decreased A/W subgroup, 29.7 (2.3) years in the no-change subgroup, and 29.2 (2.3) years in the increased

A/W subgroup. C, Estimated mean (SE) number of symptoms was 7.9 (0.1) in the decreased A/W subgroup, 6.7 (0.1) in the no-change subgroup, and 7.9 (0.1) in the increased A/W subgroup. D, Sex-adjusted BMI analyses included 9 of 14 data sets providing BMI data for more than 80% of patients. Estimated mean (SE) sex-adjusted BMIs were 27.3 (0.5) in the decreased A/W subgroup, 27.4 (0.5) in the no-change subgroup, and 30.2 (0.5) in the increased A/W. Error bars indicate SEs.

[a] Compared with the no-change subgroup.

[b] Compared with the increased A/W subgroup.

models with random intercept (data set). Analyses based on genomic relationship matrix–restricted maximum likelihood methods were applied to estimate (1) the variance in liability to MDD subgroups explained by the joint effect of all SNPs (h^2 SNP value) and (2) genetic correlations (rg value) across MDD subgroups and with BMI. The association of GPRS-LDpred with MDD subgroups was estimated using logistic mixed models with random intercept (data set). The proportion of variance explained by GPRS on the liability scale for MDD subgroups was estimated according to Lee et al.[36] Statistical significance level was set at $P < .05$ (2-tailed).

Results

Phenotype Validation

Data included 11 837 patients with MDD and 14 791 controls, for a total of 26 628 participants (59.1% female and 40.9% male). We

validated MDD subgroup phenotypes against established clinical characteristics (**Figure 1**). The increased A/W subgroup was more likely to be female compared with the decreased A/W (odds ratio [OR], 1.39; 95% CI, 1.22-1.57) and no-change (OR, 1.94; 95% CI, 1.71-2.22) subgroups and had slightly earlier age at onset compared with the decreased A/W subgroup ($\beta = -0.91$; SE = 0.32). The increased A/W ($\beta = 1.24$; SE = 0.04) and decreased A/W ($\beta = 1.23$; SE = 0.03) subgroups had higher similar severity indexed by number of endorsed symptoms than the no-change subgroup. Finally, the increased A/W subgroup had higher BMI than the decreased A/W ($\beta = 2.94$; SE = 0.18) and no-change ($\beta = 2.78$; SE = 0.19) subgroups. In addition, the increased A/W subgroup had higher BMI than controls ($\beta = 2.00$; SE = 0.70) (eFigure 1 in the Supplement); all other subgroups did not differ from controls. Direct comparisons of the increased A/W with decreased A/W subgroups by using meta-analyses highlighted moderate to substantial heterogeneity across data sets ($I^2 = 15\%$-91%) (eMethods 1 and eFigure 2 in the Supplement).

Table 2. SNP Heritability and Genetic Correlation Estimates for MDD Subgroups

MDD Subgroup	MDD Subgroup, Estimate (SE)[a,b]			
	All MDD	Decreased A/W	No Change	Increased A/W
All MDD	h^2-SNP = 0.14 (0.08)	NA	NA	NA
Decreased A/W	NA	h^2-SNP = 0.11 (0.02)	NA	NA
No change	NA	rg = 1.00 (0.23)	h^2-SNP = 0.08 (0.02)	NA
Increased A/W	NA	rg = 0.82 (0.25)	rg = 1.00 (0.40)	h^2-SNP = 0.11 (0.03)

Abbreviations: A/W, appetite and/or weight symptoms; MDD, major depressive disorder; NA, not applicable; SNP, single-nucleotide polymorphism.

[a] Results are derived from (bivariate) genomic relationship matrix–restricted maximum likelihood analyses adjusted for sex, 10 ancestry-informative principal components, and 13 data set dummy variables as genetic correlation

(rg value) or joint effect of all SNPs (h^2-SNP value). Lifetime risk for MDD, 0.150; decreased A/W subgroup (45% of patients), 0.0675; no-change subgroup (30% of patients), 0.045; and increased A/W (16% of patients), 0.024.

[b] $P < 1 \times 10^{-4}$ for estimates greater than 0.

MDD Subgroup SNP Heritability and Correlations

The genomic relationship matrix–restricted maximum likelihood analyses (Table 2) showed that the joint effect of common SNPs (h^2-SNP) significantly captured approximately 10% of variance in liability for MDD and the subgroups (eTable 3 in the Supplement for h^2-SNP at varying lifetime risk). The h^2-SNP estimates were consistent with those obtained from concurrent techniques (eMethods 1 in the Supplement). Bivariate genomic relationship matrix–restricted maximum likelihood analyses across subgroups showed an rg of 1.00 between the no-change subgroup and the increased and decreased A/W subgroups. A smaller correlation (rg = 0.82), although with large SEs owing to restricted sample sizes, was found between the decreased and increased A/W and MDD subgroups, suggesting the possibility of a specific small divergence between these 2 subgroups that otherwise shared most of their genetic background.

Differential Associations With Obesity-Related Liability

To investigate whether the smaller resemblance between the decreased and increased A/W subgroups could be attributed to a different underlying liability to obesity, we estimated their genetic correlation with BMI (estimated h^2-SNP = 0.18; SE = 0.02; $P = 2.9 \times 10^{-15}$). As depicted in **Figure 2** (MDD reported as the benchmark), BMI was significantly correlated with increased A/W (rg = 0.53; SE = 0.16) and inversely correlated with decreased A/W (rg = −0.28; SE = 0.15).

Furthermore, associations with GPRS-LDpred for obesity-related traits confirmed partially distinct polygenic signatures (**Figure 3** and eTable 4 in the Supplement) for both A/W subgroups. The GPRS-LDpred for BMI was significantly associated with a higher likelihood of increased A/W (OR, 1.18; 95% CI, 1.12-1.25; h^2 for liability = 0.56%) and with a slightly reduced likelihood of decreased A/W (OR, 0.96; 95% CI, 0.93-0.99; h^2 for liability = 0.03%; false discovery rate, q <0.05, accounting for multiple testing) (eMethods 1 in the Supplement). Moreover, the association between GPRS-LDpred for CRP levels and MDD (OR, 1.01; 95% CI, 1.01-1.06; h^2 for liability = 0.03%) seemed to be completely driven by increased A/W (OR, 1.08; 95% CI, 1.02-1.13; h^2 for liability = 0.09%). Finally, increased A/W was associated with GPRS-LDpred for leptin levels (OR, 1.09; 95% CI, 1.06-1.12; h^2 for liability = 0.14%) and, although with a reduced effect size, GPRS-LDpred for leptin levels adjusted for BMI (OR, 1.06; 95% CI, 1.01-1.12; h^2 for liability = 0.07%). Of note, GPRS-LDpred for leptin levels adjusted

Figure 2. Genetic Correlations Between Major Depressive Disorder (MDD) and Body Mass Index (BMI)


Results from bivariate genomic relationship matrix–restricted maximum likelihood analyses were adjusted for sex, 10 ancestry-informative principal components, and 8 data set dummy variables. Analyses were based on 7 data sets providing BMI data in more than 80% of the samples, including control individuals. P values test the hypothesis that h^2 values are significantly greater than 0. A/W indicates appetite and/or weight symptoms; rg, genetic correlation. Error bars indicate SEs; rg, genetic correlation.

for BMI was not associated with BMI (β = 0.07; SE = 0.04; P = .08). The associations between increased A/W and the GPRS-LDpred for obesity-related traits were similar across sex (GPRS-LDpred × sex interaction terms, P > .3) In supplementary analyses, GPRS-LDpred for MDD and schizophrenia were similarly associated across subgroups (eTable 4 in the Supplement). For completeness of information, eTable 5 in the Supplement reports the association between the no-change A/W MDD subgroup and GPRS-LDpred.

Additional Analyses With GWAS

The association of decreased and increased A/W with single genetic variants was estimated in the following 3 GWAS meta-analyses: (1) decreased A/W subgroup vs controls, (2) increased A/W subgroup vs controls, and (3) decreased vs increased A/W subgroups (eMethods 1 in the Supplement). Owing to small sample size, the 3 GWASs performed were substantially underpowered to detect significant association with

Figure 3. Associations of Polygenic Risk for Obesity-Related Traits With Major Depressive Disorder (MDD)

Results (odds ratios [ORs] and 95% CIs) from binary (using controls for reference values) logistic mixed models adjusted for sex and 5 ancestry-informative principal components. BMI indicates body mass index; CRP, C-reactive protein.

[a] False discovery rate, $q < 0.05$.

[b] Analyses were based on 13 of 14 data sets available that are not included in the discovery genome-wide association study.

single genetic variants. Only when comparing the decreased and increased A/W subgroups, 1 SNP reached genome-wide statistical significance (rs7598414; $P = 4.7 \times 10^{-8}$), harbored in a locus on chromosome 2 overlapping several genes, including *SOS1* (NG_007530.1), *CDKL4* (NC_000002.12), and *MAP4K3* (NG_028007.1) (eFigures 3-5 in the Supplement); *CDKL4* was statistically significant in gene-based test analyses ($P = 8.3 \times 10^{-7}$).

Discussion

Using data from more than 25 000 samples from the PGC-MDD2, we examined whether subgroups of patients with MDD stratified according to the *DSM* A/W symptoms had a different degree of genetic overlap with obesity-related traits. The findings showed that the derived subgroups largely shared their genetic background but were specifically divergent in their liability to immunometabolic traits, with approximately 15% of patients reporting increased A/W symptoms during an active episode carrying a higher number of common risk variants for BMI and CRP and leptin levels.

Despite the simple clinical subphenotyping strategy, the subgroups recapitulated some clinical features that were reported in previous research on classic MDD subtypes; patients with increased A/W (approximating an atypical subtype) were more likely to be female and had an earlier age at onset, higher severity, and higher BMI.[24,25] Common vari-

ants explained approximately 10% of MDD heritability, in line with the estimation from the latest PGC-MDD2 GWAS (http://www.biorxiv.org/content/early/2017/07/24/167577). The SNP heritability was similar for MDD subgroups, indicating an overall common genetic background. Reciprocal genetic correlations confirmed the close association of the subgroups. Nevertheless, the correlation of 0.82 (affected by large uncertainty owing to limited sample size) for the decreased vs increased A/W subgroups was suggestive of a possible small divergence between these 2 subgroups otherwise sharing most of their genetic background. We tested whether this divergence was attributable to obesity-related genetic variants of traits. Results confirmed that BMI had a genetic correlation with increased A/W. Similarly, the increased A/W subgroup had a higher genetic risk load for CRP and leptin levels.

Evidence from observational studies suggests stronger links with obesity immunometabolic dysregulations in depression with atypical features[14-23]; in particular, the role of increased appetite in connection to BMI and levels of CRP and leptin has been highlighted.[26,27] The present findings suggest that these phenotypic interrelationships may be rooted in a shared genetic base and common pathophysiologic mechanisms. Adipose tissue produces proinflammatory cytokines, which in turn act on peripheral cellular targets, leading to the synthesis of acute phase proteins (CRP from hepatocytes) responsible for systemic inflammation.[3] Systemic inflammation in turn could trigger brain inflammatory responses participating in depression neu-

rochemical and endocrine processes.[5] Obesity-related inflammation can disrupt the central signaling of leptin (CRP directly inhibits the binding of leptin to its receptors[37]), blunting its anorexigenic effect and consequently disinhibiting feeding.[7] In parallel, reduced central signaling affects leptin's antidepressant effects.[8-10] The hypothesis of a divergent mechanism acting in MDD along the A/W axis is strengthened by the finding of a dissociable neural response among subgroups of patients stratified according to appetite symptom, in particular with those endorsing increased appetite showing a specific hyperactivation of mesocorticolimbic reward circuitry in response to food stimuli.[38]

The present findings indicate genetic overlap between increased A/W and immunometabolic traits. Therefore, the phenotypic association between increased A/W and obesity-related features may have resulted from shared genetic and biological pathways (ie, pleiotropy), such as increased inflammation or leptin system dysregulation, rather than from an overrepresentation of participants with higher BMI among this MDD subgroup independent from these pathways (ie, confounding). The 2 processes cannot be disentangled statistically in observational data; if a pleiotropic action between 2 traits is subsumed, reciprocal adjustment for the other trait (eg, BMI) may represent a potential bias-inducing overadjustment.[39] The example of leptin is emblematic of consistent pleiotropic (and BMI-independent) actions at different levels. In animal models, leptin resistance induced through selective deletion of leptin receptor in hypothalamus or hippocampus and cortex produces hyperleptinemia with obesity[40] or depressionlike phenotypes, respectively.[41,42] Previous results from NESDA[27] showed that hyperleptinemia was linked with increased appetite in patients with MDD independently from BMI. In the present study, increased A/W was also associated with a polygenic score for BMI-adjusted leptin levels.

Although leptin may be an example of pleiotropic action of common genetic variants influencing increased A/W and obesity through specific pathways (eg, leptin effect in different brain areas[40-42]), pleiotropy also may occur when one trait is causally associated with another trait[43,44]; in this case, a genetic overlap with inflammation may occur if, for instance, the genetically determined increase in appetite and feeding would be the main driver of proinflammatory activation. Reliable discrimination of different pleiotropy scenarios with recently developed techniques[43] will become possible with the availability in the future of adequately powered GWAS for MDD subgroups. By assuming the example of leptin dysregulation as a shared mechanism, the hypothetical model is that of a subgroup of patients expected to show phenotypically average higher appetite and weight compared with others.[15] When depression ensues, the shared mechanism may become more dysregulated, and therefore, the behavioral phenotype will be more pronounced during an active episode. We confirmed using NESDA data (eResults in the Supplement) that the increased A/W subgroup had significantly higher BMI compared with other patients when the disorder was nonactive, but this difference was enhanced at the beginning of an active episode mainly owing to BMI increases in the increased A/W subgroup and decreases in the decreased A/W subgroup. This theoretical model is also consistent with the reported moderation effect of depression on the association of BMI and the *FTO* gene (NG_012969.1).[45,46]

Furthermore, this model is consistent with a conceptual framework similar to Research Domain Criteria,[47] in which biology-based multilevel dimensions cut through symptom-based clinical categories. Obesity and atypical depression may partially overlap on the dimension of energy homeostasis, which could be measured at genetic, biomarker (immunometabolic mediators), and behavior (appetite and/or feeding) levels.

Limitations

In interpreting results from the present study, some limitations should be considered. First, A/W symptoms used for case stratification were based on a single MDD episode (index lifetime episode, generally with the highest severity). Nevertheless, these symptoms are consistently 75% to 85% stable across MDD episodes, especially atypical-like increase,[48-50] indicating that they may be considered stable features of depression in an individual. Second, the data structure did not allow us to dissociate the specific effects of appetite from weight. Nevertheless, the correlation between these 2 symptoms during an active episode is high, and previous studies[26,29,51] showed that higher genetic burden for BMI or immunometabolic biomarkers were detected in patients identified only by appetite. Finally, results cannot be generalized to a population of non-European ancestry.

Conclusions

The present findings showed that the increased A/W subgroup had a specific genetic overlap with obesity-related traits. An important follow-up study would be the identification of the specific genetic loci involved using unbiased genome-wide scans. The present results indicate that at the current stage, stratification of the existing MDD GWAS data set is not yet a viable option, because the reduction in power owing to reduced sample size would not be compensated by a higher heritability of the trait (similar to MDD), as shown by the substantially null results obtained using the present data. The significant locus detected in a case-only GWAS contrasting the decreased and increased A/W subgroups should be considered mainly as a stimulus to further pursue this analytic strategy in larger data sets. Furthermore, the present results identified only associations. Once the specific loci are identified, follow-up functional studies will be needed to elucidate the potential causal role of the related pathways. Finally, although we specifically focused on A/W symptoms, future studies should consider other axes of variation in the association between MDD and genetic and biological factors, including other symptoms such as sleep disturbances or interaction with environmental factors.

The present findings may have important translational implications, providing molecular ground to the observed heterogeneity of response observed in intervention studies. For instance, anti-inflammatory agents have been proposed for depression treatment, and a recent meta-analysis[52] of randomized placebo-controlled trials indicated substantial heterogeneity in their antidepressant effects. Of interest, post hoc analyses of a previous trial showed that anti-inflammatory agents exerted antidepressant effects only in patients with high baseline CRP levels.[53] These data underline the need to iden-

tify subgroups of patients who may benefit most from a specific treatment according to a personalized medicine approach. In the present study, increased A/W symptoms identified a subgroup of approximately 15% of patients with MDD with a higher genetic risk for immunometabolic dysregulations. Future clinical trials should plan to test treatment efficacy across patients with depression stratified according to this criterion, especially for treatments targeting immunometabolic pathways (eg, anti-inflammatory agents[5] or weight reduction pharmacologic or behavioral interventions with or without recombinant leptin[7]). Development of tailored treatments effectively targeting immunometabolic dysregulations may benefit this specific subgroup of patients with MDD and obesity, both of which are associated with disability.

Author Affiliations: Department of Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience, Vrije Universiteit Medical Center and GGZ inGeest, Amsterdam, the Netherlands (Milaneschi, Lamers, Peyrot, Penninx); Discipline of Psychiatry, University of Adelaide, Adelaide, Australia (Baune); Medical Research Council Social Genetic and Developmental Psychiatry Centre, King's College London, London, England (Breen, Lewis, Mullins, Rivera); National Institute for Health Research Biomedical Research Centre for Mental Health, King's College London, London, England (Breen); Department of Epidemiology and Biostatistics, Imperial College London, London, England (Dehghan); Institute of Human Genetics, University of Bonn, Bonn, Germany (Forstner); Life Brain Center, Department of Genomics, University of Bonn, Bonn, Germany (Forstner); Department of Psychiatry, University of Basel, Basel, Switzerland (Forstner); Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland (Forstner); Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland (Forstner); Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany (Grabe, Van der Auwera); Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Germany (Homuth); Department of Psychological Medicine, King's College London, London, England (Kan); South London and Maudsley National Health Service Foundation, London, England (Kan); German Centre for Cardiovascular Research, Partner Site Greifswald, University Medicine, University Medicine Greifswald, Greifswald, Germany (Nauck); Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany (Nauck); Department of Psychiatry, University Hospital of Lausanne, Prilly, Switzerland (Pistis, Preisig); Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada, Spain (Rivera); Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (Rietschel, Streit, Strohmaier); Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany (Teumer); Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia (Wray); Queensland Brain Institute, University of Queensland, Brisbane, Australia (Wray); Department of Biological Psychology, VU University Amsterdam, Amsterdam, the Netherlands (Boomsma).

Author Contributions: Dr Lamers and Mr Peyrot contributed equally to this study. Dr Milaneschi had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analyses.
Study concept and design: Milaneschi, Lamers, Peyrot, Boomsma, Penninx.
Acquisition, analysis, or interpretation of data: Milaneschi, Lamers, Peyrot, Boomsma. Pennix.
Drafting of the manuscript: Milaneschi, Lamers, Peyrot, Boomsma, Penninx.
Critical revision of the manuscript for important intellectual content: Lamers, Peyrot, Baune, Breen, Dehghan, Forstner, Grabe, Homuth, Kan, Lewis, Mullins, Nauck, Pistis, Preisig, Rivera, Rietschel, Streit, Strohmaier, Teumer, Van der Auwera, Wray, Boomsma, Penninx.
Statistical analysis: Milaneschi, Peyrot.
Obtained funding: Lewis, Breen, Grabe, Preisig, Rietschel, Wray, Boomsma, Pennix.
Administrative, technical, or material support: Milaneschi, Peyrot, Lewis, Wray.
Study supervision: Boomsma, Penninx.

Group Information: Abbas Degan is a member of the CHARGE Inflammation Working Group. The Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, which provided the data infrastructure for the present study, include the following: Naomi R. Wray, Institute for Molecular Bioscience and Queensland Brain Institute, The University of Queensland, Brisbane, Australia; Stephan Ripke, Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte, Berlin, Germany, and Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts; Manuel Mattheisen, Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, Department of Biomedicine and iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, Denmark, and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Denmark; Maciej Trzaskowski, Institute for Molecular Bioscience, The University of Queensland; Enda M. Byrne, Institute for Molecular Bioscience, The University of Queensland; Abdel Abdellaoui, Department of Biological Psychology and EMGO, Institute for Health and Care Research, Vrije Universiteit (VU) Amsterdam, Amsterdam, the Netherlands; Mark J Adams, Division of Psychiatry, University of Edinburgh, Edinburgh, Scotland; Esben Agerbo, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Centre for Integrated Register-based Research and National Centre for Register-Based Research, Aarhus University; Tracy M. Air, Discipline of Psychiatry, University of Adelaide, Adelaide, Australia; Till F. M. Andlauer, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Silviu-Alin Bacanu, Department of Psychiatry, Virginia Commonwealth University, Richmond; Marie Bækvad-Hansen, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark; Aartjan T. F. Beekman, Department of Psychiatry, VU Medical Center and GGZ inGeest; Tim B. Bigdeli, Department of Psychiatry, Virginia Commonwealth University, and Virginia Institute for Psychiatric and Behavior Genetics, Richmond; Elisabeth B. Binder, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, and Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia; Douglas H. R. Blackwood, Division of Psychiatry, University of Edinburgh; Julien Bryois, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; Henriette N. Buttenschøn, iSEQ, Centre for Integrative Sequencing, Aarhus University, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus University, and Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut; Jonas Bybjerg-Grauholm, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut; Na Cai, Human Genetics, Wellcome Trust Sanger Institute, and Statistical Genomics and Systems Genetics, European Bioinformatics Institute, Cambridge, England; Enrique Castelao, Department of Psychiatry, University Hospital of Lausanne, Prilly, Switzerland; Jane Hvarregaard Christensen, Department of Biomedicine and iSEQ, Centre for Integrative Sequencing, Aarhus University, and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research; Toni-Kim Clarke, Division of Psychiatry, University of Edinburgh; Jonathan R. I. Coleman, Medical Research Council (MRC) Social Genetic and Developmental Psychiatry Centre, King's College London, London, England; Lucía Colodro-Conde, Genetics and Computational Biology, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute, Herston, Australia; Baptiste Couvy-Duchesne, Centre for Advanced Imaging and Queensland Brain Institute, The University of Queensland, Saint Lucia, Australia; Nick Craddock, Psychological Medicine, Cardiff University, Cardiff, Wales; Gregory E. Crawford, Center for Genomic and Computational Biology and Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, North Carolina; Gail Davies, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh; Ian J. Deary, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh; Franziska Degenhardt, Institute of Human Genetics and Life and Brain Center, Department of Genomics, University of Bonn, Bonn, Germany; Eske M. Derks, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute; Nese Direk, Epidemiology, Erasmus MC, Rotterdam, Zuid-Holland, the Netherlands, and Psychiatry, Dokuz Eylul University School of Medicine, Izmir, Turkey; Conor V. Dolan, Department of Biological Psychology and EMGO, Institute for Health and Care Research, Vrije Universiteit; Erin C. Dunn, Department of Psychiatry and Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, Massachusetts, and Stanley Center for Psychiatric Research, Broad Institute; Thalia C. Eley, MRC Social Genetic and Developmental Psychiatry Centre, King's College London; Valentina Escott-Price, Neuroscience and Mental Health, Cardiff University; Farnush Farhadi Hassan Kiadeh, Bioinformatics, University of British Columbia, Vancouver, Canada; Hilary K. Finucane, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, and Department of Mathematics, Massachusetts Institute of Technology, Cambridge; Andreas J. Forstner, Institute of Human Genetics and Life and Brain Center, Department of Genomics, University of Bonn, and Department of Psychiatry (UPK) and Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland; Josef Frank, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Héléna A. Gaspar, MRC Social Genetic and Developmental Psychiatry Centre, King's College London; Michael Gill, Department of Psychiatry, Trinity College Dublin, Dublin, Ireland; Fernando S. Goes, Psychiatry and Behavioral Sciences, The Johns Hopkins University, Baltimore, Maryland; Scott D. Gordon, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute; Jakob Grove, Department of Biomedicine, iSEQ, Centre for Integrative Sequencing, and Bioinformatics Research Centre, Aarhus University, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research; Lynsey S. Hall, Division of Psychiatry, University of Edinburgh, and Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, England; Christine Søholm Hansen, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut; Thomas F. Hansen, iPSYCH, The Lundbeck Foundation Initiative for Psychiatric Research, Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, and Institute of Biological Psychiatry, Mental Health Center Sankt Hans, Mental Health Services Capital Region of Denmark, Copenhagen; Stefan Herms, Institute of Human Genetics and Life and Brain Center, Department of Genomics, University of Bonn, and Human Genomics Research Group, Department of Biomedicine, University of Basel; Ian B. Hickie, Brain and Mind Centre, University of Sydney, Sydney, Australia; Per Hoffmann, Institute of Human Genetics and Life and Brain Center, Department of Genomics, University of Bonn, and Human Genomics Research Group, Department of Biomedicine, University of Basel; Georg Homuth,

Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Germany; Carsten Horn, Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd, Basel; Jouke-Jan Hottenga, Department of Biological Psychology and EMGO, Institute for Health and Care Research, VU Amsterdam; David M. Hougaard, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut; Marcus Ising, Max Planck Institute of Psychiatry, Munich, Germany; Rick Jansen, Department of Psychiatry, VU Medical Center and GGZ inGeest; Eric Jorgenson, Division of Research, Kaiser Permanente Northern California, Oakland; James A. Knowles, Psychiatry and the Behavioral Sciences, University of Southern California, Los Angeles; Isaac S. Kohane, Department of Biomedical Informatics, Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, and Informatics Program, Boston Children's Hospital, Boston, Massachusetts; Julia Kraft, Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte; Warren W. Kretzschmar, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, England; Jesper Krogh, Department of Endocrinology at Herlev University Hospital, University of Copenhagen; Zoltán Kutalik, Institute of Social and Preventive Medicine, University Hospital of Lausanne, and Swiss Institute of Bioinformatics, Lausanne, Switzerland; Yihan Li, Informatics Program, Boston Children's Hospital; Penelope A. Lind, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute; Donald J. MacIntyre, Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, and Mental Health, NHS 24, Glasgow, Scotland; Dean F. MacKinnon, Psychiatry and Behavioral Sciences, The Johns Hopkins University; Robert M. Maier, Queensland Brain Institute, The University of Queensland; Wolfgang Maier, Department of Psychiatry and Psychotherapy, University of Bonn; Jonathan Marchini, Statistics, University of Oxford; Hamdi Mbarek, Department of Biological Psychology and EMGO, Institute for Health and Care Research, VU Amsterdam; Patrick McGrath, Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Peter McGuffin, MRC Social Genetic and Developmental Psychiatry Centre, King's College London; Sarah E. Medland, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute; Divya Mehta, Queensland Brain Institute, The University of Queensland, and School of Psychology and Counseling, Queensland University of Technology; Christel M. Middeldorp, Department of Biological Psychology and EMGO, Institute for Health and Care Research, VU Amsterdam, Child and Youth Mental Health Service, Children's Health Queensland Hospital and Health Service, South Brisbane, and Child Health Research Centre, University of Queensland; Evelin Mihailov, Estonian Genome Center, University of Tartu, Tartu; Yuri Milaneschi, Department of Psychiatry, VU Medical Center and GGZ inGeest; Lili Milani, Estonian Genome Center, University of Tartu; Francis M. Mondimore, Psychiatry and Behavioral Sciences, The Johns Hopkins University; Grant W. Montgomery, Institute for Molecular Bioscience, The University of Queensland; Sara Mostafavi, Medical Genetics and Statistics, University of British Columbia, Vancouver, Canada; Niamh Mullins, MRC Social Genetic and Developmental Psychiatry Centre, King's College London; Matthias Nauck, German Centre for Cardiovascular Research, Partner Site Greifswald, and Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany; Bernard Ng, Statistics, University of British Columbia; Michel G. Nivard, Department of Biological Psychology and EMGO, Institute for Health and Care Research, VU Amsterdam; Dale R. Nyholt, Institute of Health and Biomedical Innovation, Queensland University of Technology; Paul F. O'Reilly, MRC Social Genetic and Developmental Psychiatry Centre, King's College London; Hogni Oskarsson, Humus, Reykjavik, Iceland; Michael J. Owen, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University; Jodie N. Painter, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute; Carsten Bøcker Pedersen, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Centre for Integrated Register-based Research and National Centre for Register-Based Research, Aarhus University; Marianne Giørtz Pedersen, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Centre for Integrated Register-based Research and National Centre for Register-Based Research, Aarhus University; Roseann E. Peterson, Department of Psychiatry and Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University; Erik Pettersson, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; Wouter J. Peyrot, Department of Psychiatry, VU Medical Center and GGZ inGeest; Giorgio Pistis, Department of Psychiatry, University Hospital of Lausanne; Danielle Posthuma, Clinical Genetics and Complex Trait Genetics, VU Amsterdam; Jorge A. Quiroz, Solid Biosciences, Boston, Massachusetts; Per Qvist, Department of Biomedicine and iSEQ, Centre for Integrative Sequencing, Aarhus University, and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research; John P. Rice, Department of Psychiatry, Washington University in St Louis School of Medicine, St Louis, Missouri; Brien P. Riley, Department of Psychiatry, Virginia Commonwealth University; Margarita Rivera, MRC Social Genetic and Developmental Psychiatry Centre, King's College London, and Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada, Spain; Saira Saeed Mirza, Epidemiology, Erasmus MC; Robert Schoevers, Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Eva C. Schulte, Department of Psychiatry and Psychotherapy and Institute of Psychiatric Phenomics and Genomics (IPPG), Medical Center of the University of Munich, Campus Innenstadt, Munich, Germany; Ling Shen, Division of Research, Kaiser Permanente Northern California, Oakland; Jianxin Shi, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland; Stanley I. Shyn, Behavioral Health Services, Kaiser Permanente Washington, Seattle; Engilbert Sigurdsson, Faculty of Medicine, Department of Psychiatry, University of Iceland, Reykjavik; Grant C. B. Sinnamon, School of Medicine and Dentistry, James Cook University, Townsville, Australia; Johannes H. Smit, Department of Psychiatry, VU Medical Center and GGZ inGeest; Daniel J. Smith, Institute of Health and Wellbeing, University of Glasgow; Hreinn Stefansson, deCODE Genetics/Amgen, Reykjavik; Stacy Steinberg, deCODE Genetics/Amgen; Fabian Streit, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University; Jana Strohmaier, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University; Katherine E. Tansey, College of Biomedical and Life Sciences, Cardiff University; Henning Teismann, Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany; Alexander Teumer, Institute for Community Medicine, University Medicine Greifswald; Wesley Thompson, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Institute of Biological Psychiatry, Mental Health Center Sankt Hans, Mental Health Services Capital Region of Denmark, Department of Psychiatry, University of California, San Diego, and KG Jebsen Centre for Psychosis Research, Norway Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Pippa A. Thomson, Medical Genetics Section, Centre for Genomic and Experimental Medicine (CGEM), Institute of Genetics and Molecular Medicine (IGMM), University of Edinburgh; Thorgeir E. Thorgeirsson, deCODE Genetics/Amgen; Matthew Traylor, Clinical Neurosciences, University of Cambridge, Cambridge, England; Jens Treutlein, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University; Vassily Trubetskoy, Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte; André G. Uitterlinden, Internal Medicine, Erasmus MC, Rotterdam; Daniel Umbricht, Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Medicine Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd, Basel; Sandra Van der Auwera, Department of Psychiatry and Psychotherapy, University Medicine Greifswald; Albert M. van Hemert, Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands; Alexander Viktorin, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; Peter M. Visscher, Institute for Molecular Bioscience and Queensland Brain Institute, The University of Queensland; Yunpeng Wang, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Institute of Biological Psychiatry, Mental Health Center Sankt Hans, Mental Health Services Capital Region of Denmark, Institute of Epidemiology and Social Medicine, University of Münster; Bradley T. Webb, Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University; Shantel Marie Weinsheimer, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Institute of Biological Psychiatry, Mental Health Center Sankt Hans, Mental Health Services Capital Region of Denmark; Jürgen Wellmann, Institute of Epidemiology and Social Medicine, University of Münster; Gonneke Willemsen, Department of Biological Psychology and EMGO, Institute for Health and Care Research, Vrije Universiteit

Amsterdam; Stephanie H. Witt, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University; Yang Wu, Institute for Molecular Bioscience, The University of Queensland; Hualin S. Xi, Computational Sciences Center of Emphasis, Pfizer Global Research and Development, Cambridge, Massachusetts; Jian Yang, Institute for Molecular Bioscience, Queensland Brain Institute, The University of Queensland; Futao Zhang, Institute for Molecular Bioscience, The University of Queensland; Volker Arolt, Department of Psychiatry, University of Münster; Bernhard T. Baune, Discipline of Psychiatry, University of Adelaide; Klaus Berger, Institute of Epidemiology and Social Medicine, University of Münster; Dorret I. Boomsma, Department of Biological Psychology and EMGO, Institute for Health and Care Research, VU Amsterdam; Sven Cichon, Institute of Human Genetics, University of Bonn, Human Genomics Research Group, Department of Biomedicine, and Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, and Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Juelich, Denmark; Udo Dannlowski, Department of Psychiatry, University of Münster; E. J. C. de Geus, Department of Biological Psychology and EMGO, Institute for Health and Care Research, and Amsterdam Public Health Institute, Vrije Universiteit Medical Center, Amsterdam; J. Raymond DePaulo, Psychiatry and Behavioral Sciences, The Johns Hopkins University; Enrico Domenici, Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy; Katharina Domschke, Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Denmark; Tõnu Esko, Medical and Population Genetics, Broad Institute, and Estonian Genome Center, University of Tartu; Hans J. Grabe, Department of Psychiatry and Psychotherapy, University Medicine Greifswald; Steven P. Hamilton, Psychiatry, Kaiser Permanente Northern California, San Francisco; Caroline Hayward, MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh; Andrew C. Heath, Department of Psychiatry, Washington University in Saint Louis School of Medicine; Kenneth S. Kendler, Department of Psychiatry, Virginia Commonwealth University; Stefan Kloiber, Max Planck Institute of Psychiatry, and Department of Psychiatry, University of Toronto, and Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Glyn Lewis, Division of Psychiatry, University College London, London, England; Qingqin S. Li, Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, New Jersey; Susanne Lucae, Max Planck Institute of Psychiatry; Pamela A. F. Madden, Department of Psychiatry, Washington University in Saint Louis School of Medicine; Patrik K. Magnusson, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; Nicholas G. Martin, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute; Andrew M. McIntosh, Division of Psychiatry and Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh; Andres Metspalu, Estonian Genome Center and Institute of Molecular and Cell Biology, University of Tartu; Ole Mors, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research and

Psychosis Research Unit, Aarhus University Hospital; Preben Bo Mortensen, iSEQ, Centre for Integrative Sequencing, Centre for Integrated Register-based Research, and National Centre for Register-Based Research, Aarhus University, and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research; Bertram Müller-Myhsok, Discipline of Psychiatry, University of Adelaide, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, and University of Liverpool, Liverpool, England; Merete Nordentoft, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, and Mental Health Center Copenhagen, Copenhagen University Hospital; Markus M. Nöthen, Institute of Human Genetics and Life and Brain Center, Department of Genomics, University of Bonn; Michael C. O'Donovan, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University; Sara A. Paciga, Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, Connecticut; Nancy L. Pedersen, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; Brenda W. J. H. Penninx, Department of Psychiatry, VU Medical Center and GGZ inGeest; Roy H. Perlis, Department of Psychiatry, Massachusetts General Hospital, and Psychiatry, Harvard Medical School, Boston, Massachusetts; David J. Porteous, Medical Genetics Section, CGEM, IGMM, University of Edinburgh; James B. Potash, Psychiatry, University of Iowa, Iowa City; Martin Preisig, Department of Psychiatry, University Hospital of Lausanne; Marcella Rietschel, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University; Catherine Schaefer, Division of Research, Kaiser Permanente Northern California, Oakland; Thomas G. Schulze, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, IPPG, Medical Center of the University of Munich, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, and Human Genetics Branch, National Institute of Mental Health Division of Intramural Research Programs, Bethesda, Maryland; Jordan W. Smoller, Department of Psychiatry and PNGU, Massachusetts General Hospital, and Stanley Center for Psychiatric Research, Broad Institute; Kari Stefansson, deCODE Genetics/Amgen and Faculty of Medicine, University of Iceland, Reykjavik; Henning Tiemeier, Epidemiology, Child and Adolescent Psychiatry, and Psychiatry, Erasmus MC; Rudolf Uher, Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; Henry Völzke, Institute for Community Medicine, University Medicine Greifswald; Myrna M. Weissman, Psychiatry, Columbia University College of Physicians and Surgeons, and Division of Epidemiology, New York State Psychiatric Institute, New York; Thomas Werge, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Institute of Biological Psychiatry, Mental Health Center Sankt Hans, Mental Health Services Capital Region of Denmark, and Department of Clinical Medicine, University of Copenhagen; Cathryn M. Lewis, MRC Social Genetic and Developmental Psychiatry Centre and Department of Medical and Molecular Genetics, King's College London; Douglas F. Levinson, Psychiatry and Behavioral Sciences, Stanford University, Stanford,

California; Gerome Breen, MRC Social Genetic and Developmental Psychiatry Centre and NIHR BRC for Mental Health, King's College London; Anders D Børglum, Department of Biomedicine and iSEQ, Centre for Integrative Sequencing, Aarhus University, and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research; and Patrick F Sullivan, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Genetics and Psychiatry, University of North Carolina at Chapel Hill.

REFERENCES

1. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry*. 2010;67(3):220-229. doi:10.1001/archgenpsychiatry.2010.2

2. Xu Q, Anderson D, Lurie-Beck J. The relationship between abdominal obesity and depression in the general population: a systematic review and meta-analysis. *Obes Res Clin Pract*. 2011;5(4):e267-e360. doi:10.1016/j.orcp.2011.04.007

3. Penninx BWJH, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC Med*. 2013;11:129. doi:10.1186/1741-7015-11-129

4. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. *Nat Med*. 2012;18(3):363-374. doi:10.1038/nm.2627

5. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol*. 2016;16(1):22-34. doi:10.1038/nri.2015.5

6. Pace TWW, Miller AH. Cytokines and glucocorticoid receptor signaling: relevance to major depression. *Ann N Y Acad Sci*. 2009;1179(1):86-105. doi:10.1111/j.1749-6632.2009.04984.x

7. van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. *Cell*. 2015;161(1):119-132. doi:10.1016/j.cell.2015.03.008

8. Lu X-Y. The leptin hypothesis of depression: a potential link between mood disorders and obesity? *Curr Opin Pharmacol*. 2007;7(6):648-652. doi:10.1016/j.coph.2007.10.010

9. Garza JC, Guo M, Zhang W, Lu X-Y. Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3β/β-catenin signaling. *Mol Psychiatry*. 2012;17(8):790-808. doi:10.1038/mp.2011.161

10. Yamada N, Katsuura G, Ochi Y, et al. Impaired CNS leptin action is implicated in depression associated with obesity. *Endocrinology*. 2011;152(7):2634-2643. doi:10.1210/en.2011-0004

11. Farr OM, Tsoukas MA, Mantzoros CS. Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders. *Metabolism*. 2015;64(1):114-130. doi:10.1016/j.metabol.2014.07.004

12. Bouret SG. Neurodevelopmental actions of leptin. *Brain Res*. 2010;1350:2-9. doi:10.1016/j.brainres.2010.04.011

13. Licinio J, Mantzoros C, Negrão AB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. *Nat Med*. 1997;3(5):575-579.

14. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman ATF, Penninx BWJH. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. *Mol Psychiatry*. 2013;18(6):692-699. doi:10.1038/mp.2012.144

15. Lamers F, Beekman ATF, van Hemert AM, Schoevers RA, Penninx BWJH. Six-year longitudinal course and outcomes of subtypes of depression. *Br J Psychiatry*. 2016;208(1):62-68. doi:10.1192/bjp.bp.114.153098

16. Kaestner F, Hettich M, Peters M, et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. *J Affect Disord*. 2005;87(2-3):305-311. doi:10.1016/j.jad.2005.03.012

17. Rudolf S, Greggersen W, Kahl KG, Hüppe M, Schweiger U. Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. *Psychiatry Res*. 2014;217(1-2):34-38. doi:10.1016/j.psychres.2014.02.016

18. Sullivan PF, Prescott CA, Kendler KS. The subtypes of major depression in a twin registry. *J Affect Disord*. 2002;68(2-3):273-284.

19. Hasler G, Pine DS, Gamma A, et al. The associations between psychopathology and being overweight: a 20-year prospective study. *Psychol Med*. 2004;34(6):1047-1057.

20. Levitan RD, Davis C, Kaplan AS, Arenovich T, Phillips DIW, Ravindran AV. Obesity comorbidity in unipolar major depressive disorder: refining the core phenotype. *J Clin Psychiatry*. 2012;73(8):1119-1124. doi:10.4088/JCP.11m07394

21. Cizza G, Ronsaville DS, Kleitz H, et al; POWER (Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Study Group. Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study. *PLoS One*. 2012;7(1):e28912. doi:10.1371/journal.pone.0028912

22. Lasserre AM, Glaus J, Vandeleur CL, et al. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. *JAMA Psychiatry*. 2014;71(8):880-888. doi:10.1001/jamapsychiatry.2014.411

23. Lasserre AM, Strippoli M-PF, Glaus J, et al. Prospective associations of depression subtypes with cardio-metabolic risk factors in the general population. *Mol Psychiatry*. 2017;22(7):1026-1034. doi:10.1038/mp.2016.178

24. Lamers F, de Jonge P, Nolen WA, et al. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). *J Clin Psychiatry*. 2010;71(12):1582-1589. doi:10.4088/JCP.09m05398blu

25. Novick JS, Stewart JW, Wisniewski SR, et al; STAR*D investigators. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. *J Clin Psychiatry*. 2005;66(8):1002-1011.

26. Lamers F, Milaneschi Y, de Jonge P, Giltay EJ, Penninx BWJH. Metabolic and inflammatory markers: associations with individual depressive symptoms [published online September 11, 2017]. *Psychol Med*. doi:10.1017/S0033291717002483

27. Milaneschi Y, Lamers F, Bot M, Drent ML, Penninx BWJH. Leptin dysregulation is specifically associated with major depression with atypical features: evidence for a mechanism connecting obesity and depression. *Biol Psychiatry*. 2017;81(9):807-814. doi:10.1016/j.biopsych.2015.10.023

28. Milaneschi Y, Lamers F, Mbarek H, Hottenga J-J, Boomsma DI, Penninx BW. The effect of *FTO* rs9939609 on major depression differs across MDD subtypes. *Mol Psychiatry*. 2014;19(9):960-962. doi:10.1038/mp.2014.4

29. Milaneschi Y, Lamers F, Peyrot WJ, et al. Polygenic dissection of major depression clinical heterogeneity. *Mol Psychiatry*. 2016;21(4):516-522. doi:10.1038/mp.2015.86

30. Locke AE, Kahali B, Berndt SI, et al; LifeLines Cohort Study; ADIPOGen Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium; International Endogene Consortium. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518(7538):197-206. doi:10.1038/nature14177

31. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation*. 2011;123(7):731-738. doi:10.1161/CIRCULATIONAHA.110.948570

32. Kilpeläinen TO, Carli JFM, Skowronski AA, et al. Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. *Nat Commun*. 2016;7:10494. doi:10.1038/ncomms10494

33. Ripke S, Neale BM, Corvin A, et al; Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427. doi:10.1038/nature13595

34. Vilhjálmsson BJ, Yang J, Finucane HK, et al; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) study. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am J Hum Genet*. 2015;97(4):576-592. doi:10.1016/j.ajhg.2015.09.001

35. Palla L, Dudbridge F. A fast method that uses polygenic scores to estimate the variance explained by genome-wide marker panels and the proportion of variants affecting a trait. *Am J Hum Genet*. 2015;97(2):250-259. doi:10.1016/j.ajhg.2015.06.005

36. Lee SH, Goddard ME, Wray NR, Visscher PM. A better coefficient of determination for genetic profile analysis. *Genet Epidemiol*. 2012;36(3):214-224. doi:10.1002/gepi.21614

37. Chen K, Li F, Li J, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. *Nat Med*. 2006;12(4):425-432. doi:10.1038/nm1372

38. Simmons WK, Burrows K, Avery JA, et al. Depression-related increases and decreases in appetite: dissociable patterns of aberrant activity in reward and interoceptive neurocircuitry. *Am J Psychiatry*. 2016;173(4):418-428. doi:10.1176/appi.ajp.2015.15020162

39. Aschard H, Vilhjálmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies.

40. Ring LE, Zeltser LM. Disruption of hypothalamic leptin signaling in mice leads to early-onset obesity, but physiological adaptations in mature animals stabilize adiposity levels. *J Clin Invest*. 2010;120(8):2931-2941. doi:10.1172/JCI41985

41. Guo M, Huang T-Y, Garza JC, Chua SC, Lu X-Y. Selective deletion of leptin receptors in adult hippocampus induces depression-related behaviours. *Int J Neuropsychopharmacol*. 2013;16(4):857-867. doi:10.1017/S1461145712000703

42. Guo M, Lu X-Y. Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates. *Transl Psychiatry*. 2014;4(12):e486. doi:10.1038/tp.2014.126

43. Gratten J, Visscher PM. Genetic pleiotropy in complex traits and diseases: implications for genomic medicine. *Genome Med*. 2016;8(1):78. doi:10.1186/s13073-016-0332-x

44. Middeldorp CM, Cath DC, Van Dyck R, Boomsma DI. The co-morbidity of anxiety and depression in the perspective of genetic epidemiology: a review of twin and family studies. *Psychol Med*. 2005;35(5):611-624. doi:10.1017/S003329170400412X

45. Rivera M, Cohen-Woods S, Kapur K, et al. Depressive disorder moderates the effect of the *FTO* gene on body mass index. *Mol Psychiatry*. 2012;17(6):604-611. doi:10.1038/mp.2011.45

46. Rivera M, Locke AE, Corre T, et al. Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals. *Br J Psychiatry*. 2017;211(2):70-76. doi:10.1192/bjp.bp.116.183475

47. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. *BMC Med*. 2013;11:126. doi:10.1186/1741-7015-11-126

48. Lamers F, Rhebergen D, Merikangas KR, de Jonge P, Beekman ATF, Penninx BWJH. Stability and transitions of depressive subtypes over a 2-year follow-up. *Psychol Med*. 2012;42(10):2083-2093. doi:10.1017/S0033291712000141

49. Nierenberg AA, Pava JA, Clancy K, Rosenbaum JF, Fava M. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? *Biol Psychiatry*. 1996;40(8):691-696. doi:10.1016/0006-3223(96)00029-7

50. Stunkard AJ, Fernstrom MH, Price A, Frank E, Kupfer DJ. Direction of weight change in recurrent depression: consistency across episodes. *Arch Gen Psychiatry*. 1990;47(9):857-860. doi:10.1001/archpsyc.1990.01810210065009

51. Milaneschi Y, Sutin AR, Terracciano A, et al. The association between leptin and depressive symptoms is modulated by abdominal adiposity. *Psychoneuroendocrinology*. 2014;42:1-10. doi:10.1016/j.psyneuen.2013.12.015

52. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. *JAMA Psychiatry*. 2014;71(12):1381-1391. doi:10.1001/jamapsychiatry.2014.1611

53. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry*. 2013;70(1):31-41. doi:10.1001/2013.jamapsychiatry.4

Am J Hum Genet. 2015;96(2):329-339. doi:10.1016/j.ajhg.2014.12.021